Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,214 total articles
Gilat Satellite Networks announced a successful demonstration of its breakthrough AI-based interference detection and cancellation technology for satellite links. This patent-pending solution significantly improves interference mitigation by up to 10 times compared to conventional methods, maintaining signal integrity even under challenging interfe…
Aya Gold & Silver Inc. announced the acquisition of a significant exploration portfolio in Morocco, adding 259 km² of land across three projects (Zagora, Agadir-Melloul, and Goulmim). This acquisition increases their total land holdings by 35.4%, strengthens their district-scale exploration strategy, and enhances exposure to precious, base, and cri…
Priovant Therapeutics has commenced patient enrollment in the global Phase 3 BEACON+ trial evaluating brepocitinib for cutaneous sarcoidosis (CS), following positive Phase 2 results and FDA Breakthrough Therapy Designation. The drug is also progressing in multiple orphan disease indications including dermatomyositis, non-infectious uveitis, and lic…
Roivant Sciences reported Q1 FY2027 financial results and provided an update on key pipeline developments. The company is preparing for the commercial launch of brepocitinib for dermatomyositis by September 2026 and expects topline data later this year for several late-stage trials including non-infectious uveitis, cutaneous sarcoidosis, and pulmon…
Immunocore Holdings plc reported robust second quarter 2026 financial results, highlighted by 18% year-over-year growth in net revenues for KIMMTRAK reaching $115.9 million. The company is advancing multiple Phase 3 clinical trials, including the TEBE-AM trial for advanced cutaneous melanoma and the PRISM-MEL-301 trial for first-line melanoma, with…
Korro Bio announced its Q2 2026 financial results, highlighting progress in its OPERA platform technology with the upcoming first-in-human trial for KRRO-121 in hyperammonemia and orphan drug designation from the EMA. The company also nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), demonstrating significant …
Immunovant, a clinical-stage immunology company, announced its financial results for the quarter ended June 30, 2026, highlighting a cash position sufficient to support the potential launch of IMVT-1402 in Graves’ disease. The company reported increased R&D expenses reflecting advancement in clinical trials across six indications including Graves’ …
Cartesian Therapeutics reported Q2 2026 financial results and business updates highlighting progress in its CAR-T cell therapy pipeline targeting autoimmune diseases including myasthenia gravis, myositis, and juvenile dermatomyositis. The company secured a strategic licensing agreement with WestGene to develop an in vivo CAR-T platform, expects mul…
Peloton Interactive, Inc. announced its Q4 and full fiscal year 2026 financial results, highlighting its first full year of GAAP net profitability with net income of $63 million and an Adjusted EBITDA of $468 million, a 16% year-over-year increase. Total revenue reached $2.446 billion, slightly above guidance, driven by strong equipment sales. The …
Foghorn Therapeutics provided its Q2 2026 update highlighting progress in its clinical-stage programs, including the Phase 1 dose escalation of FHD-909 targeting SMARCA4-mutant NSCLC, advancement of selective EP300 and CBP degrader programs for hematological malignancies and breast cancer, and initiation of a novel oral immunology inflammation prog…
American Shared Hospital Services announced its upcoming Q2 2026 financial results conference call, highlighting continued growth and expansion in stereotactic radiosurgery, Gamma Knife, proton therapy, and advanced radiation cancer treatments. The company collaborates with health systems to share in capital investment and profitability while focus…
Intellia Therapeutics announced promising Phase 3 clinical trial results for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene editing candidate for hereditary angioedema (HAE), demonstrating significant attack reduction and favorable safety profile. The company expects FDA acceptance of a biologics license application (BLA) in the second hal…
Sotera Health Company delivered strong financial performance in Q2 and the first half of 2026, with double-digit increases in net income and Adjusted EBITDA margins. The company raised its full-year 2026 revenue and Adjusted EBITDA growth outlook, driven by solid growth across its three business segments: Sterigenics, Nordion, and Nelson Labs. Impr…
KVH Industries reported a 27% increase in total revenues for Q2 2026 compared to the same quarter last year, driven by a substantial rise in low earth orbit (LEO) service sales primarily from Starlink and OneWeb subscribers. Service revenues grew significantly while product sales saw an 11-12% increase. The company highlights strategic progress in …
Lantheus Holdings, a US-listed radiopharmaceutical company, reported second quarter 2026 revenue of $388.2 million, up 2.7% year-over-year, with adjusted earnings per share slightly down to $1.55. The company announced a definitive agreement for an $8.0 billion all-cash merger with Curium US Holdings LLC, valuing Lantheus shares at $102.50 per shar…
Climb Bio, Inc., a clinical-stage biotechnology company focused on immune-mediated diseases, reported its second quarter 2026 financial results and provided updates on key clinical programs. The company highlighted progress in its CLYM116 and budoprutug trials, including upcoming Phase 1 and 2 data presentations and ongoing enrollment. A $110 milli…
Datadog announced its second quarter 2026 financial results with $1.12 billion in revenue, representing 36% year-over-year growth. The company reported positive free cash flow of $279 million and maintained a solid customer base expansion, with approximately 4,720 customers generating over $100k ARR, up 23% from the prior year. Datadog also launche…
Fiserv, Inc. reported its second quarter 2026 financial results showing a 4% decrease in GAAP revenue and 37% decline in GAAP earnings per share compared to the prior year. Both Merchant Solutions and Financial Solutions segments experienced revenue declines. The company also updated its 2026 organic revenue outlook to a range of -1% to 0% and adju…
USA Rare Earth, a Nasdaq-listed company focused on rare earth metals and permanent magnets, announced it will release its financial results for Q2 2026 on August 10, followed by a conference call to discuss outcomes and operational progress. The company is advancing its integrated supply chain spanning mining, metal production, and magnet manufactu…
Mangoceuticals announced that Nuclea Energy, its merger partner, has signed a non-binding MOU with New Mining Co. to assess the feasibility of deploying Nuclea's advanced modular nuclear reactors to provide behind-the-meter power for New Mining's high-density Bitcoin mining data centers. The phased evaluation could lead to up to 100 MWe capacity, s…
Opus Genetics, a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced second quarter 2026 financial results and provided updates on its pipeline. Key milestones include completion of enrollment in the OPGx-LCA5 registrational trial with dosing planned for Q4 2026, upcoming topline data from OP…
Cullinan Therapeutics provided an update on its clinical programs advancing T cell engagers for autoimmune diseases and cancer, highlighting upcoming multi-dose regimen data for CLN-978 and velinotamig, progression to Phase 2 studies in 2027, and a potentially registrational Phase 2 trial for CLN-049 in relapsed/refractory AML starting Q3 2026. The…
Avalo Therapeutics reported second quarter 2026 financial results highlighting positive topline Phase 2 results for its lead drug candidate, abdakibart, in hidradenitis suppurativa (HS). The company plans to initiate a registrational Phase 3 clinical program in the first half of 2027 and has expanded its pipeline with AVTX-010, a next-generation an…
Monte Rosa Therapeutics announced robust Q2 2026 results featuring significant clinical and development milestones, including completed enrollment in a key MRT-8102 study targeting cardiovascular disease risk, activation of multiple Phase 2 trials across inflammatory and oncology programs, and a strong financial position with $626 million in cash t…
Generate Biomedicines Inc. reported continued progress in its clinical programs and platform advancements during Q2 2026. The company is advancing its Phase 3 SOLAIRIA studies for GB-0895 in severe asthma, enrolling patients globally, and will present Phase 1b data for GB-0895 in COPD at the ERS Congress. It also dosed the first cohort in a Phase 1…
